Brief: Arch Biopartners Receives Independent Institutional Review Board Approval For Phase Ii Trial For Lsalt Peptide
04/08/2020 14:47
Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS RECEIVES INDEPENDENT INSTITUTIONAL REVIEW
BOARD
APPROVAL FOR PHASE II TRIAL FOR LSALT PEPTIDE
Source text for Eikon: ID:nGNX5dlBM4
Further company coverage: ARCH.V
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide